GleamWall
中文EN

ABEO ABEONA THERAPEUTICS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 318306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-175.9%
TTM EPS YoY-189.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin65.1%
Operating margin-186.1%
Net margin-160.3%
FCF margin-170.1%
EBITDA margin-178.5%

Returns

ROE-42.1%
ROA-31.0%
ROIC (approx.)-59.9%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets26.8%
Debt / equity0.19x
Current ratio5.69x
Interest coverage-24.47x

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue7.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$13.49M$11.38M$8.72M$5.42M$0$400,000——
Cost of revenue$5.71M$4.18M$2.70M$1.04M$488,000———
Gross profit$7.78M$7.20M$6.02M$4.38M-$488,000———
R&D expense$3.67M$5.02M$9.55M$6.71M$4.22M$5.94M$9.94M$8.99M
SG&A expense$17.11M$15.84M$19.50M$18.78M$19.31M$17.15M$9.79M$7.68M
Operating income-$13.00M-$13.65M-$23.03M-$22.91M-$24.02M-$22.79M-$19.73M-$16.67M
Interest expense$557,000$696,000$830,000$884,000$901,000$957,000$998,000$1.08M
Pretax income-$4.79M-$20.19M-$17.07M-$20.68M-$20.36M$124.34M-$12.03M-$9.29M
Income tax$18,000$0$2,000-$215,000-$15.20M$15.51M——
Net income-$4.81M-$20.19M-$17.07M-$20.46M-$5.16M$108.83M-$12.03M-$9.29M
EBITDA-$12.30M-$12.95M-$22.34M-$22.05M-$23.42M-$22.19M-$19.19M-$16.13M
EPS (basic)-0.08-0.35-0.30—-0.102.07-0.24—
EPS (diluted)-0.08-0.35-0.30—-0.101.71-0.24—
Weighted avg. shares (diluted)57.86M57.05M56.62M—54.24M66.64M49.78M—
Balance sheet
Cash & equivalents$66.28M$56.23M$61.37M$78.44M$82.88M$163.53M$15.94M$23.36M
Short-term investments$68.66M$90.60M$106.90M$112.97M$124.23M$61.98M$68.22M$74.36M
Receivables$15.73M$9.39M$6.20M$6.15M————
Inventory$4.66M$5.92M$6.05M$5.49M$4.85M$2.69M——
Current assets$157.72M$164.58M$182.99M$204.91M$216.13M$232.26M$88.12M$100.85M
PP&E, net$9.49M$10.15M$10.56M$9.92M$10.34M$9.49M$6.95M$4.43M
Total assets$171.92M$179.51M$198.49M$219.57M$231.09M$246.23M$99.36M$108.93M
Current liabilities$27.71M$24.81M$31.05M$29.57M$22.18M$34.52M$17.98M$16.59M
Short-term debt$11.85M$13.33M$13.33M$12.22M$8.89M$5.56M$8.15M$5.93M
Long-term debt$11.85M$1.66M$4.75M$7.81M$10.86M$14.01M$11.14M$13.04M
Total debt$23.69M$14.99M$18.09M$20.04M$19.75M$19.56M$19.29M$18.96M
Total liabilities$46.05M$51.45M$53.55M$60.35M$59.86M$82.66M$57.97M$64.90M
Shareholders' equity$125.88M$128.06M$144.94M$159.22M$171.23M$163.58M$41.40M$44.03M
Net debt-$42.59M-$41.24M-$43.29M-$58.40M-$63.13M-$143.97M$3.35M-$4.39M
Shares outstanding57.17M57.23M56.87M55.04M52.40M51.25M48.95M45.64M
Cash flow statement
Operating cash flow-$8.31M-$17.50M-$19.80M-$17.95M-$21.19M-$18.78M-$18.40M-$16.56M
Capital expenditure$219,000$479,000$935,000$1.15M$2.52M$2.90M$1.40M$606,000
Free cash flow-$8.53M-$17.98M-$20.74M-$19.11M-$23.71M-$21.68M-$19.80M-$17.16M
Investing cash flow$21.70M$15.69M$4.96M$9.55M-$64.63M$155.89M$4.21M$18.88M
Financing cash flow-$3.34M-$3.33M-$2.22M$3.61M$5.16M$10.49M$6.77M$5.31M
Depreciation & amortization$700,000$700,000$690,000$863,000$600,000$600,000$534,000$539,000
Stock-based compensation$2.79M$3.37M$2.96M$2.56M$2.69M$2.83M$2.70M$1.96M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.